An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-Leaving Booster to 14-15-Year-Old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5 and half Years of Age.

Trial Profile

An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-Leaving Booster to 14-15-Year-Old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5 and half Years of Age.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Acronyms Tdap Booster
  • Most Recent Events

    • 31 Mar 2012 Actual end date (8 Oct 2009) as reported by European Clinical Trials Database.
    • 31 Mar 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 04 Jun 2010 Planned end date changed from 1 Feb 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top